Mirati Therapeutics, Inc.
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

Abstract:

The present disclosure relates to compounds of Formula (I), or pharmaceutically, acceptable salts thereof, that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present disclosure relates to compounds, or pharmaceutically acceptable salts thereof pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising compounds of Formula (I), or pharmaceutically acceptable salts thereof. ##STR00001##